This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hyatt, J. M.
Right arrow Articles by Schentag, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hyatt, J. M.
Right arrow Articles by Schentag, J. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, 08 1995, 1711-1716, Vol 39, No. 8
Copyright © 1995 by the American Society for Microbiology. All rights reserved.

In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa

JM Hyatt, DE Nix, CW Stratton and JJ Schentag
Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, Buffalo, New York 14209-1194, USA.

The time-kill curve methodology was used to determine the pharmacodynamics of piperacillin, ciprofloxacin, piperacillin- tazobactam and the combinations piperacillin-ciprofloxacin and ciprofloxacin-piperacillin-tazobactam. Kill curve studies were performed for piperacillin, ciprofloxacin, and piperacillin-tazobactam at concentrations of 0.25 to 50 times the MICs for 13 strains of bacteria: four Pseudomonas aeruginosa, three Enterobacter cloacae, three Klebsiella pneumoniae, and three Staphylococcus aureus isolates (tazobactam concentrations of 0.5, 4, and 12 micrograms/ml). By using a sigmoid Emax model and nonlinear least squares regression, the 50% lethal concentrations and the maximum lethal rates of each agent were determined for each bacterial strain. For piperacillin-ciprofloxacin and ciprofloxacin-piperacillin-tazobactam, kill curve studies were performed with concentrations obtained by the fractional maximal effect method (R. C. Li, J. J. Schentag, and D. E. Nix, Antimicrob. Agents Chemother. 37:523-531, 1993) and from individual 50% lethal concentrations and maximum lethal rates. Ciprofloxacin-piperacillin- tazobactam was evaluated only against the four P. aeruginosa strains. Interactions between piperacillin and ciprofloxacin were generally additive. At physiologically relevant concentrations of piperacillin and ciprofloxacin, ciprofloxacin had the highest rates of killing against K. pneumoniae. Piperacillin-tazobactam (12 micrograms/ml) had the highest rate of killing against E. cloacae. Piperacillin- ciprofloxacin with relatively higher ciprofloxacin concentrations had the greatest killing rates against S. aureus. This combination had significantly higher killing rates than piperacillin (P < 0.002). For all the bacterial strains tested, killing rates by ciprofloxacin were significantly higher than those by piperacillin-tazobactam (4 and 12 micrograms/ml had significantly higher killing rates than piperacillin alone (P < 0.02 and P < 0.004, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:

  • Bull, J. J, Regoes, R. R (2006). Pharmacodynamics of non-replicating viruses, bacteriocins and lysins. Proc R Soc B 273: 2703-2712 [Abstract] [Full Text]  
  • Olofsson, S. K., Geli, P., Andersson, D. I., Cars, O. (2005). Pharmacodynamic Model To Describe the Concentration-Dependent Selection of Cefotaxime-Resistant Escherichia coli. Antimicrob. Agents Chemother. 49: 5081-5091 [Abstract] [Full Text]  
  • Regoes, R. R., Wiuff, C., Zappala, R. M., Garner, K. N., Baquero, F., Levin, B. R. (2004). Pharmacodynamic Functions: a Multiparameter Approach to the Design of Antibiotic Treatment Regimens. Antimicrob. Agents Chemother. 48: 3670-3676 [Abstract] [Full Text]  
  • Mouton, J. W., van Ogtrop, M. L., Andes, D., Craig, W. A. (1999). Use of Pharmacodynamic Indices To Predict Efficacy of Combination Therapy In Vivo. Antimicrob. Agents Chemother. 43: 2473-2478 [Abstract] [Full Text]  
  • MacGowan, A. P., Wootton, M., Holt, H. A. (1999). The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosaassessed by combining antibiotic exposure and bacterial susceptibility. J Antimicrob Chemother 43: 345-349 [Abstract] [Full Text]